After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr
After its disappointing Rova-T flop last month, AbbVie is shoring up its solid tumor bets with a freshly inked research deal that should elicit …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
